log in
Print | Back

Morris, Manning & Martin, LLP

Michael X. Ye, Ph. D.

Michael X. Ye, Ph. D.

Partner

Expertise

  • Corporate
  • Intellectual Property
  • Patents/Trademarks/Copyrights
  • Technology

WSG Practice Industries

Activity

Profile
Dr. Michael Ye is a Partner in the firm’s Intellectual Property Practice, specifically in the fields of biotechnology, chemistry, bioinformatics, cosmetics, pharmaceuticals, and medical devices. He works directly with investors and in-house counsel to draft and prosecute patent applications and engages in the preparation of patentability, validity, and related opinions. Dr. Ye handles inter partes review and post grant proceedings, product clearance searches, product evaluations, inventorship analysis, non-disclosure agreements, and licensing agreements.

Dr. Ye has practiced before the U.S. Patent and Trademark Office since 2001. He was an assistant professor of biochemistry and molecular biology at The George Washington University and the Children’s National Medical Center from 1997 to 2002. His research experience includes:

- Development of adenoviral and AAV vectors and delivery methods for gene therapy.

- In utero gene transfer and induction of cellular and humeral immune tolerance by prenatal and neonatal immunization.

- Evaluation of immune responses and pharmacokinetics of therapeutic gene expression following viral administration.

- Development of inducible expression systems for controlled transgene expression.

- Evaluation of autoimmune responses to tumor antigens.

- Signal transduction mechanism and vaccine development.

Dr. Ye has authored or co-authored 28 peer-reviewed scientific articles. He was the recipient of the National Institutes of Health’s National Research Service Award and the recipient of the Award for Scientific and Academic Achievement from the Children’s National Medical Center.

Bar Admissions

District of Columbia, 2006
Maryland, 2005
New Jersey, 2005
U.S. Court of Appeals for the Federal Circuit
U.S. Patent and Trademark Office

Education

Georgetown University Law Center, J.D., 2004
University of Pennsylvania, Ph.D. Biochemistry, 1993
Peking University, B.S. Biochemistry, 1985
Areas of Practice

Corporate | Intellectual Property | Patents/Trademarks/Copyrights | Technology

Professional Career

Significant Accomplishments

Named “One of the World’s Leading Patent Practitioners” for Patent Prosecution in Washington, D.C., Intellectual Management magazine’s IAM Patent 1000: The World’s Leading Patent Practitioners (2016, 2017)

Seminars

“Recent Development in Gene Therapy,” presented at the U.S. Patent and Trademark Office Educational Session for Patent Examiners, 2005.
Articles

“New Proposed Rules Regarding Government Rights in Federally Funded Research,” February 21, 2017.

“Winning The Battle But Losing The War?” New Considerations For File Wrapper Estoppel, December 22, 2014.

“The Myriad Decision in the U.S. Supreme Court IP and Technology Developments,” Special Edition, BIO Conference, July 10, 2012.

“Is an Isolated DNA Patentable?” IP and Technology Developments, October 25, 2011.

X. Ye, J. McCarrick, L. Jewett and B.B. Knowles, “Timely immunization subverts the development of peripheral non-responsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice,” Proc. Natl. Acad. Sci. USA 91, 3916-3920, 1994.

J.F. Engelhardt, X. Ye, B. Doranz, and J.M. Wilson, “Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver,” Proc. Natl. Acad. Sci. USA 91, 6196-6200, 1994.

X. Ye, M.B. Robinson, M.L. Batshaw, E.E. Furth, I. Smith, and J.M. Wilson, “Prolonged metabolic correction in adult ornithine transcarbamylase deficiency mice with adenoviral vectors,” J. Biol. Chem. 271, 3639-3646, 1996.

X. Ye, G. Gao, Carol Pabin, S. E. Raper, and J. M. Wilson, “Evaluating the potential of germline transmission after intravenous administration of recombinant adenovirus in the C3H mouse,” Human Gene Therapy, Vol. 9, 2135-2142, 1998.

X. Ye, V.M. Rivera, P. Zoltick, F. Cerasoli, M.A. Schnell, G. Gao, J.V. Hughes, M. Gilman, and J.M. Wilson, “Regulated delivery of therapeutic proteins following in vivo somatic cell gene transfer,” Science, 283, 88-91, 1999.

V.M. Rivera, X. Ye, N.L. Courage, F. Cerasoli, Jr., J.M. Wilson, and M. Gilman, “Long-term regulated gene expression in mice following intramuscular gene transfer,” Proceedings of the National Academy of Sciences of the USA, 96:8657-8662, 1999.

X. Ye, M. Jerebtsova, and P.E. Ray, “Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine and kidney,” Human Gene Therapy, 11:621-628, 2000.

X. Ye, B. Whiteman, M. Jerebtsova, and M.L. Batshaw, “Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA,” Gene Therapy, 7:1777-1782, 2000.

X. Ye, M.B. Robinson, C. Pabin, M.L. Batshaw, and J.M. Wilson, “Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mice,” Gene Therapy, 7:1761-1767, 2000.

X. Ye, X. Liu, Z. Li, and P.E. Ray, “Efficient gene transfer to rat renal glomeruli with recombinant adenoviral vectors,” Human Gene Therapy, 12:141-148, 2001.

X. Ye, K.P. Zimmer, R. Brown, C. Pabin, M.L. Batshaw, J.M. Wilson, and M.B. Robinson, “Differences in the human and mouse amino terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors,” Human Gene Therapy 12:1035-1046, 2001.

X. Ye, M. Jerebtsova, X. Liu, Z. Li, and P.E. Ray, “Adenovirus-mediated gene transfer to renal glomeruli in rodents,” Kidney International 61 Suppl 1:16-23, 2002.


WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020